$39.85
0.83[2.13%]
At close: Apr 24
$39.85
0[0.00%]
After Hours: 4:00PM EDT
IDEAYA Biosciences
(NASDAQ:IDYA)IDEAYA Biosciences Stock (NASDAQ:IDYA), Analyst Ratings, Price Targets, Predictions
IDEAYA Biosciences Inc has a consensus price target of $39.87, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Citigroup, BTIG, and JP Morgan on March 21, 2024, March 8, 2024, and February 23, 2024. With an average price target of $57.33 between Citigroup, BTIG, and JP Morgan, there's an implied 43.87% upside for IDEAYA Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
BTIG
JP Morgan
RBC Capital
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for IDEAYA Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/21/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 50.56% | Citigroup | Yigal Nochomovitz | $40 → $60 | Maintains | Buy | Get Alert |
| 03/08/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 38.02% | BTIG | Justin Zelin | → $55 | Initiates | → Buy | Get Alert |
| 02/23/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 43.04% | JP Morgan | Anupam Rama | $51 → $57 | Maintains | Overweight | Get Alert |
| 02/21/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 33% | RBC Capital | Gregory Renza | $43 → $53 | Maintains | Outperform | Get Alert |
| 01/26/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 33% | Goldman Sachs | Corinne Jenkins | $36 → $53 | Maintains | Buy | Get Alert |
| 01/25/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 33% | Goldman Sachs | Corinne Jenkins | $36 → $53 | Maintains | Buy | Get Alert |
| 01/10/2024 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 7.9% | RBC Capital | Gregory Renza | $36 → $43 | Maintains | Outperform | Get Alert |
| 12/06/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -9.66% | RBC Capital | Gregory Renza | → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/30/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 2.89% | JP Morgan | Anupam Rama | $35 → $41 | Maintains | Overweight | Get Alert |
| 11/13/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 7.9% | Wedbush | Robert Driscoll | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 11/08/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 10.41% | Guggenheim | Vanck Zhu | $48 → $44 | Maintains | Buy | Get Alert |
| 11/08/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 7.9% | Wedbush | Robert Driscoll | → $43 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -9.66% | RBC Capital | Gregory Renza | $32 → $36 | Maintains | Outperform | Get Alert |
| 10/11/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -19.7% | RBC Capital | Gregory Renza | → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 09/12/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 7.9% | Wedbush | Robert Driscoll | $40 → $43 | Maintains | Outperform | Get Alert |
| 09/12/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -7.15% | Goldman Sachs | Corinne Jenkins | $31 → $37 | Maintains | Buy | Get Alert |
| 08/17/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -19.7% | JP Morgan | Anupam Rama | $28 → $32 | Maintains | Overweight | Get Alert |
| 08/11/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | -19.7% | RBC Capital | Gregory Renza | $30 → $32 | Maintains | Outperform | Get Alert |
| 08/11/2023 | IDYA | Buy Now | IDEAYA Biosciences | $39.85 | 0.38% | Wedbush | Robert Driscoll | $35 → $40 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for IDEAYA Biosciences (IDYA)?
The latest price target for IDEAYA Biosciences (NASDAQ: IDYA) was reported by Citigroup on March 21, 2024. The analyst firm set a price target for $60.00 expecting IDYA to rise to within 12 months (a possible 50.56% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for IDEAYA Biosciences (IDYA)?
The latest analyst rating for IDEAYA Biosciences (NASDAQ: IDYA) was provided by Citigroup, and IDEAYA Biosciences maintained their buy rating.
When was the last upgrade for IDEAYA Biosciences (IDYA)?
The last upgrade for IDEAYA Biosciences Inc happened on April 24, 2023 when Stifel raised their price target to $24. Stifel previously had a hold for IDEAYA Biosciences Inc.
When was the last downgrade for IDEAYA Biosciences (IDYA)?
The last downgrade for IDEAYA Biosciences Inc happened on August 15, 2022 when Stifel changed their price target from $16 to $13 for IDEAYA Biosciences Inc.
When is the next analyst rating going to be posted or updated for IDEAYA Biosciences (IDYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEAYA Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEAYA Biosciences was filed on March 21, 2024 so you should expect the next rating to be made available sometime around March 21, 2025.
Is the Analyst Rating IDEAYA Biosciences (IDYA) correct?
While ratings are subjective and will change, the latest IDEAYA Biosciences (IDYA) rating was a maintained with a price target of $40.00 to $60.00. The current price IDEAYA Biosciences (IDYA) is trading at is $39.85, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.